Optimax Access is a UK-based Health Economics and Outcome Research (HEOR) consultancy company based in the United Kingdom, with an office in the Netherlands as well. We assist our clients in introducing their pharmaceutical and biotech products, and services to major global healthcare markets. We will help you to identify a clear and optimal pathway to success with a comprehensive catalog of services ranging from clinical study design to reimbursement assessment, health economics evidence generation and health technology assessment dossier submission.

Optimax Access has been a preferred business partner for HEOR services for iGES Life Sciences Group (a 40-year-old company based in Germany with multiple offices in Europe) since 2019.


A blend of experience from consultancy, industry and academia

Prof Dr Bertram Häussler

Prof Dr. Bertram Häussler (Ph.D.) is head of the iGES group He is an honorary professor at the Technical University of Berlin in “Economics of the Pharmaceutical Industry His scientific focus is on industrial economics, health economics, health care research, benefit assessment, and drug development

Dr Amir Ansaripour

Dr Amir Ansaripour (Ph.D.) is a health economist. He has collaborated with pharma companies from different countries in cost-effectiveness analyses of new technologies for various diseases.
His Ph.D. research focused on cost-effectiveness analyses, modeling, and reimbursement policy analysis. During past years, he has applied various methods such as questionnaire/survey analysis, data mining on a large claims database, real-world cost analysis, Markov modeling, pharmaceutical pricing, and market access strategy in his projects.

Dr Mehdi Javanbakht

Chief Executive Officer

Mehdi holds a Ph.D. in Health Economics and has over 14 years of experience in academia and industry. He used to work as an ERG member for NICE. Mehdi has built over 80 economic evaluation models from scratch for different diseases (Cancer, diabetes, cardiovascular diseases, Ophthalmology, …) and has over 120 publications in high impact journals. He has a strong commercial sense and in-depth knowledge of modeling.

Atefeh Mashayekhi

Head of Evidence Synthesis Team
Atefeh was an Evidence Synthesis Analyst at NIHR Innovation Observatory. She was also a member of the Evidence Synthesis and Health Economics Teams in the Institute of Health & Society. She has a strong background in health economics and Evidence Synthesis. She has published several Cochrane systematic reviews.

Eoin Moloney

Senior Health Economist

Eoin Moloney (MSc) is a senior health economist, with over eight years’ experience in academia and industry. He has worked across a wide range of clinical disease areas, focussing on the cost-effectiveness and budget-impact of a variety of medical and pharmaceutical interventions. He has a strong track record of publications in high-impact clinical and economic journals, and an in-depth understanding of the methods required to demonstrate the cost-effectiveness of new technologies.

Jennifer Head – Independent Business Development Manager

Jennifer has worked in the healthcare industry for over 15 years, in a range of commercial and operational roles. She is a passionate advocate for the adoption of innovative solutions within the Global Healthcare Market. Jennifer holds an MSc in Advanced Strategic Marketing and an MBA.

Scientific advisors

Professor Maziar Moradi-Lakeh

Head of Clinical Research Team
Maziar is a Medical Doctor with post-graduate studies in health metric and evaluation. He has been a consultant for several international organizations, governments, and companies. Maziar has contributed to publishing more than 180 papers in peer-reviewed journals.


Building successful relationships